Guo G, Raje NS, Seifer C, et al. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018;32(8):1838-1841. doi:10.1038/s41375-018-0115-z
Udeshi ND, Mani DC, Satpathy S, et al. Rapid and deep-scale ubiquitylation profiling for biology and translational research. Nat Commun. 2020;11(1):359. doi:10.1038/s41467-019-14175-1
Sievers QL, Gasser JA, Cowley GS, Fischer ES, Ebert BL. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4 activity. Blood. 2018;132(12):1293-1303. doi:10.1182/blood-2018-01-821769
Manier S, Park J, Capelletti M, et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun. 2018;9(1):1691. doi:10.1038/s41467-018-04001-5
Went M, Sud A, Law PJ, et al. Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. Blood Cancer J. 2017;7(6):e573. doi:10.1038/bcj.2017.48
Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005;102(24):8567-72. doi:10.1073/pnas.0503221102
Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91-101. doi:10.1016/j.ccr.2013.12.015
Lohr JG, Kim S, Gould J, et al. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med. 2016;8(363):363ra147. doi:10.1126/scitranslmed.aac7037
Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood. 2015;126(21):2366-9. doi:10.1182/blood-2015-07-567958
Guirguis AA, Ebert BL. Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond. Curr Opin Cell Biol. 2015;37:61-7. doi:10.1016/j.ceb.2015.10.004